These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 23198862)

  • 21. Genetically Engineered T-Cells for Malignant Glioma: Overcoming the Barriers to Effective Immunotherapy.
    Chuntova P; Downey KM; Hegde B; Almeida ND; Okada H
    Front Immunol; 2018; 9():3062. PubMed ID: 30740109
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
    Kosti P; Maher J; Arnold JN
    Front Immunol; 2018; 9():1104. PubMed ID: 29872437
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR.
    Torikai H; Reik A; Liu PQ; Zhou Y; Zhang L; Maiti S; Huls H; Miller JC; Kebriaei P; Rabinovich B; Lee DA; Champlin RE; Bonini C; Naldini L; Rebar EJ; Gregory PD; Holmes MC; Cooper LJ
    Blood; 2012 Jun; 119(24):5697-705. PubMed ID: 22535661
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current Headway in Cancer Immunotherapy Emphasizing the Practice of Genetically Engineered T Cells to Target Selected Tumor Antigens.
    Ray SK; Mukherjee S
    Crit Rev Immunol; 2021; 41(1):23-40. PubMed ID: 33822523
    [TBL] [Abstract][Full Text] [Related]  

  • 25. T-cell engineering for cancer immunotherapy.
    Sadelain M
    Cancer J; 2009; 15(6):451-5. PubMed ID: 20010162
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy.
    Ti D; Niu Y; Wu Z; Fu X; Han W
    Sci China Life Sci; 2018 Nov; 61(11):1320-1332. PubMed ID: 30414005
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.
    Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Cenciarelli C
    Cancer Med; 2021 Aug; 10(15):5019-5030. PubMed ID: 34145792
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current status of engineered T-cell therapy for synovial sarcoma.
    Dallos M; Tap WD; D'Angelo SP
    Immunotherapy; 2016 Sep; 8(9):1073-80. PubMed ID: 27485079
    [TBL] [Abstract][Full Text] [Related]  

  • 29. T Cell Engineering.
    Pircher M; Schirrmann T; Petrausch U
    Prog Tumor Res; 2015; 42():110-35. PubMed ID: 26383243
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Redirected T cells in cancer therapy.
    Sangiolo D
    Expert Opin Biol Ther; 2015; 15(12):1667-70. PubMed ID: 26515608
    [TBL] [Abstract][Full Text] [Related]  

  • 31. T cell-mediated immunotherapy of metastases: state of the art in 2005.
    Schirrmacher V
    Expert Opin Biol Ther; 2005 Aug; 5(8):1051-68. PubMed ID: 16050783
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cancer immunotherapy: Progress and challenges in the clinical setting.
    Zarour HM; Ferrone S
    Eur J Immunol; 2011 Jun; 41(6):1510-5. PubMed ID: 21618503
    [No Abstract]   [Full Text] [Related]  

  • 33. CAR T-cell Therapy: A New Era in Cancer Immunotherapy.
    Miliotou AN; Papadopoulou LC
    Curr Pharm Biotechnol; 2018; 19(1):5-18. PubMed ID: 29667553
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives.
    Qu J; Mei Q; Chen L; Zhou J
    Cancer Immunol Immunother; 2021 Mar; 70(3):619-631. PubMed ID: 33025047
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor.
    Urbanska K; Lanitis E; Poussin M; Lynn RC; Gavin BP; Kelderman S; Yu J; Scholler N; Powell DJ
    Cancer Res; 2012 Apr; 72(7):1844-52. PubMed ID: 22315351
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.
    Martinez M; Moon EK
    Front Immunol; 2019; 10():128. PubMed ID: 30804938
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adoptive cell therapy: genetic modification to redirect effector cell specificity.
    Morgan RA; Dudley ME; Rosenberg SA
    Cancer J; 2010; 16(4):336-41. PubMed ID: 20693844
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The integrin αvβ6: a novel target for CAR T-cell immunotherapy?
    Whilding LM; Vallath S; Maher J
    Biochem Soc Trans; 2016 Apr; 44(2):349-55. PubMed ID: 27068939
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic engineering of T cell specificity for immunotherapy of cancer.
    Willemsen RA; Debets R; Chames P; Bolhuis RL
    Hum Immunol; 2003 Jan; 64(1):56-68. PubMed ID: 12507815
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advances and Challenges of CAR T Cells in Clinical Trials.
    Holzinger A; Abken H
    Recent Results Cancer Res; 2020; 214():93-128. PubMed ID: 31473850
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.